CoChat

The safety and immunogenicity of two novel live attenuated monovalent (serotype 2) oral poliovirus vaccines in healthy adults: a double-blind, single-centre phase 1 study

Open access
Van Damme, Pierre, De Coster, Ilse, Bandyopadhyay, Ananda S, Revets, Hilde, Withanage, Kanchanamala, De Smedt, Philippe, Suykens, Leen, Oberste, M Steven, Weldon, William C, Costa-Clemens, Sue Ann, Clemens, Ralf, Modlin, John, Weiner, Amy J, Macadam, Andrew J, Andino, Raul, Kew, Olen M, Konopka-Anstadt, Jennifer L, Burns, Cara C, Konz, John, Wahid, Rahnuma, Gast, Christopher · 2019 · The Lancet

The DOI matches its Crossref record; 22 of the 22 references it cites were found in a registry or an index.

Abstract

BACKGROUND: Use of oral live-attenuated polio vaccines (OPV), and injected inactivated polio vaccines (IPV) has almost achieved global eradication of wild polio viruses. To address the goals of achieving and maintaining global eradication and minimising the risk of outbreaks of vaccine-derived polioviruses, we tested novel monovalent oral type-2 poliovirus (OPV2) vaccine candidates that are genetically more stable than existing OPVs, with a lower risk of reversion to neurovirulence. Our study represents the first in-human testing of these two novel OPV2 candidates. We aimed to evaluate the safety and immunogenicity of these vaccines, the presence and extent of faecal shedding, and the neurovirulence of shed virus. METHODS: In this double-blind, single-centre phase 1 trial, we isolated participants in a purpose-built containment facility at the University of Antwerp Hospital (Antwerp, Belgium), to minimise the risk of environmental release of the novel OPV2 candidates. Participants, who were recruited by local advertising, were adults (aged 18-50 years) in good health who had previously been vaccinated with IPV, and who would not have any contact with immunosuppressed or unvaccinated people for the duration of faecal shedding at the end of the study. The first participant randomly chose an envelope containing the name of a vaccine candidate, and this determined their allocation; the next 14 participants to be enrolled in the study were sequentially allocated to this group and received the same vaccine. The subsequent 15 participants enrolled after this group were allocated to receive the other vaccine. Participants and the study staff were masked to vaccine groups until the end of the study period. Participants each received a single dose of one vaccine candidate (candidate 1, S2/cre5/S15domV/rec1/hifi3; or candidate 2, S2/S15domV/CpG40), and they were monitored for adverse events, immune responses, and faecal shedding of the vaccine virus for 28 days. Shed virus isolates were tested for the genetic stability of attenuation. The primary outcomes were the incidence and type of serious and severe adverse events, the proportion of participants showing viral shedding in their stools, the time to cessation of viral shedding, the cell culture infective dose of shed virus in virus-positive stools, and a combined index of the prevalence, duration, and quantity of viral shedding in all participants. This study is registered with EudraCT, number 2017-000908-21 and ClinicalTrials.gov, number NCT03430349. FINDINGS: Between May 22 and Aug 22, 2017, 48 volunteers were screened, of whom 15 (31%) volunteers were excluded for reasons relating to the inclusion or exclusion criteria, three (6%) volunteers were not treated because of restrictions to the number of participants in each group, and 30 (63%) volunteers were sequentially allocated to groups (15 participants per group). Both novel OPV2 candidates were immunogenic and increased the median blood titre of serum neutralising antibodies; all participants were seroprotected after vaccination. Both candidates had acceptable tolerability, and no serious adverse events occurred during the study. However, severe events were reported in six (40%) participants receiving candidate 1 (eight events) and nine (60%) participants receiving candidate 2 (12 events); most of these events were increased blood creatinine phosphokinase but were not accompanied by clinical signs or symptoms. Vaccine virus was detected in the stools of 15 (100%) participants receiving vaccine candidate 1 and 13 (87%) participants receiving vaccine candidate 2. Vaccine poliovirus shedding stopped at a median of 23 days (IQR 15-36) after candidate 1 administration and 12 days (1-23) after candidate 2 administration. Total shedding, described by the estimated median shedding index (50% cell culture infective dose/g), was observed to be greater with candidate 1 than candidate 2 across all participants (2·8 [95% CI 1·8-3·5] vs 1·0 [0·7-1·6]). Reversion to neurovirulence, assessed as paralysis of transgenic mice, was low in isolates from those vaccinated with both candidates, and sequencing of shed virus indicated that there was no loss of attenuation in domain V of the 5'-untranslated region, the primary site of reversion in Sabin OPV. INTERPRETATION: We found that the novel OPV2 candidates were safe and immunogenic in IPV-immunised adults, and our data support the further development of these vaccines to potentially be used for maintaining global eradication of neurovirulent type-2 polioviruses. FUNDING: Bill & Melinda Gates Foundation.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/s0140-6736(19)31279-6

Cites

22 of 22 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1 Trial profile
Figure 1 Trial profileCC BY · PubMed Central
Figure 2 Viral shedding of the two novel oral type-2 poliovirus vaccine candidates Data are the number of PCR-positive stool samples and the log10(CCID50/g) after administration on day 0. Participants who had ceased shedding were included, at a value of 0, in the computation of the mean log10(CCID50/g). CCID50=50% cell culture infectious dose.
Figure 2 Viral shedding of the two novel oral type-2 poliovirus vaccine candidates Data are the number of PCR-positive stool samples and the log10(CCID50/g) after administration on day 0. Participants who had ceased shedding were included, at a value of 0, in the computation of the mean log10(CCID50/g). CCID50=50% cell culture infectious dose.CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

5 more claims about this paper

Create a free account to see every claim other papers make about this one.

See all claims — free account

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 22 references

Research works printed but not linked: 1

  1. Hird, 2012, Systematic review of mucosal immunity induced by oral and inactivated poliovirus vaccines against virus shedding following oral poliovirus challenge, PLoS Pathog, 8, 10.1371/journal.ppat.1002599 · DOI · Paper page

Cited by

See all 141

Metadata

Authors
Van Damme, P., De Coster, I., Bandyopadhyay, A. S., Revets, H., Withanage, K., De Smedt, P., Suykens, L., Oberste, M. S., Weldon, W. C., Costa-Clemens, S. A., Clemens, R., Modlin, J., Weiner, A. J., Macadam, A. J., Andino, R., Kew, O. M., Konopka-Anstadt, J. L., Burns, C. C., Konz, J., Wahid, R., & Gast, C.
Affiliations
  • Gates Foundation (US)
  • University of Antwerp (BE)
  • Centers for Disease Control and Prevention (US)
  • National Institute for Biological Standards and Control (GB)
  • University of California, San Francisco (US)
  • Program for Appropriate Technology in Health (US)
Venue
The Lancet
Publisher
Elsevier BV
Published
2019-07
Volume
394
Issue
10193
Pages
148-158
ISSN
  • 0099-5355 (ISSN-L)
  • 0140-6736
OpenAlex
W2948253547
Cited by
141
References
22
Citations by year
2026: 3 · 2025: 9 · 2024: 16 · 2023: 16 · 2022: 21 · 2021: 24 · 2020: 41 · 2019: 10
FWCI
17.34
Type
journal article
Language
en
Open access
Licence
Locations
  • The Lancet (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • eScholarship (California Digital Library) (submittedVersion, cc-by)
  • eScholarship (California Digital Library) (submittedVersion)
Funders
Bill and Melinda Gates Foundation
Topics
  • Health Sciences › Medicine › Infectious Diseases › Viral Infections and Immunology Research
  • Health Sciences › Medicine › Epidemiology › Virology and Viral Diseases
  • Life Sciences › Immunology and Microbiology › Virology › Poxvirus research and outbreaks
Keywords
live attenuated poliovirus vaccine, vaccine safety, vaccine immunogenicity, fecal shedding, neurovirulence, vaccine-derived poliovirus, vaccine reversion, healthy adults
MeSH terms
Immunogenicity, Vaccine, Adult, Antibodies, Viral, Double-Blind Method, Feces, Female, Humans, Male, Middle Aged, Poliomyelitis, Poliovirus Vaccine, Oral, RNA, Viral, Vaccines, Attenuated, Virulence, Single-Blind Method, Virus Shedding, Poliovirus, Young Adult

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: The safety and immunogenicity of two novel live attenuated monovalent (serotype 2) oral poliovirus vaccines in healthy adults: a double-blind, single-centre phase 1 study. https://app.cochat.ai/papers/10.1016/s0140-6736(19)31279-6
The paper
Van Damme, P., De Coster, I., Bandyopadhyay, A. S., Revets, H., Withanage, K., De Smedt, P., Suykens, L., Oberste, M. S., Weldon, W. C., Costa-Clemens, S. A., Clemens, R., Modlin, J., Weiner, A. J., Macadam, A. J., Andino, R., Kew, O. M., Konopka-Anstadt, J. L., Burns, C. C., Konz, J., . . . Gast, C. (2019). The safety and immunogenicity of two novel live attenuated monovalent (serotype 2) oral poliovirus vaccines in healthy adults: a double-blind, single-centre phase 1 study. The Lancet. https://doi.org/10.1016/s0140-6736(19)31279-6

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.